AVTX - Avalo Therapeutics, Inc.
4.45
-0.330 -7.416%
Share volume: 193,117
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$4.78
-0.33
-0.07%
View ratios
| Fiscal Date | 12-31-2024 | |
|---|---|---|
| Fiscal Quarter | Q4 2024 | |
| Report Date | 03-20-2025 | |
| Total revenue | 192.000 K | |
| Cost of revenue | -75.000 K | |
| Gross profit | 267.000 K | |
| Operating expenses | 13.416 M | |
| Selling general and admin | 5.234 M | |
| Research and development | 8.182 M | |
| Total expenses | 13.416 M | |
| Operating income | -13.309 M | |
| Ebit | -36.439 M | |
| Pretax income | -35.225 M | |
| Income tax | 114.000 K | |
| Net income basic | 0.000 | |
| Net income | -35.339 M | |
